NSAID-INDUCED GASTROPATHIES: DIAGNOSIS AND TREATMENT


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the medications most commonly used for a long time. Meanwhile, the long-term use of NSAIDs gives rise to gastro- and duodenopathies in 70% of patients so it is important to correctly choose a procedure for the treatment and prevention of NSAID-induced gastropathies.

Full Text

Restricted Access

About the authors

T. Polunina

A.I. Evdokimov Moscow State University of Medicine and Dentistry

Email: poluntan@imail.ru
Professor

References

  1. Каратеев А.Е., Насонов Е.Л. НПВП-ассоциированная патология ЖКТ: реальное состояние дел в России // РМЖ. -2006; 15; 1073-8.
  2. Маев И.В., Вьючнова Е.С., Лебедева Е.Г. Место ингибиторов протонной помпы в терапии гастропатий, индуцированных приемом нестероидных противовоспалительных препаратов // Клин. перспективы гастроэнтерол., гепа-тол. -2006; 6: 16-23.
  3. Wolfe M., Lichtenstein D., Singh G. Gastrointestinal Toxicity of Nonsteroidal Antiinflammatory Drugs // N. Engl. J. Med. - 1999; 340: 1888-99.
  4. Buscaglia J., Kalloo A., Choti M. et al. Peptic ulcer disease. Digestive disease library, 2008. www.hopkinsgi.org.
  5. Ивашкин В.Т. Рациональная фармакотерапия заболеваний органов пищеварения. Руководство для практикующих врачей / М.: Литтера, 2003.
  6. Rostom A., Dube C., Wells G. et al. Prevention of NSAIDinduced gastroduodenal ulcers (Cochrane Review). In: The Cochrane Library Issue 2 / Oxford: Update Software, 2003.
  7. Cullen D., Bardhan K., Eisner M. et al. Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users // Aliment. Pharmacol. Ther. - 1998; 12: 135-40.
  8. Ekstrom P., Carling L., Wetterhus S. et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous nonsteroidal anti-inflammatory drug therapy. A Nordic multicentre study // Scand. J. Gastroenterol. - 1996; 31: 753-8.
  9. Bianchi Porro G., Lazzaroni M., Imbresi V. et al. Efficacy of pantoprazole in the prevention of peptic ulcers, induced by non-steroidal anti-inflammatory drugs: a prospective, placebocontrolled, double-blind, parallel-group study // Dig. Liver Dis. - 2000; 32: 201-8.
  10. Stupnicki T., Dietrich K., Gonzalez-Carro P. et al. Efficacy and tolerability of pantoprazole compared with misoprostol for prevention of NSAID-related gastrointestinal lesions and symptoms in rheumatic patients // Digestion. - 2003; 68: 198-208.
  11. Regula J., Deckers C., Raps D. et al. Comparison of 20 mg and 40 mg pantoprazole vs 20 mg omeprazole in the prevention of the development of gastrointestinal lesions in rheumatic patients with continuous NSAID intake // Gut. - 2001; 49 (suppl. 3): A1229 (Abstract).
  12. Pilotto A., Di Mario F., Franceschi M. et al. Pantoprazole versus one-week Helicobacter pylori eradication therapy for the prevention of acute NSAID-related gastroduodenal damage in elderly subjects // Aliment. Pharmacol. Ther. - 2000; 14: 1077-82.
  13. Маев И.В., Андреев Д.Н., Дичева Д.Е. и др. Фармакотерапевтические аспекты применения ингибиторов протонной помпы // Мед. вестн. МВД. -2013; 3 (64): 9-14.
  14. Wedemeyer R.-S., Blume H. Drug Interaction Profiles of Proton Pump Inhibitors: An Update // Drug Saf. - 2014; 37: 201-11.
  15. Blume H., Donath F., Warnke A., et al. Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors // Drug Saf. - 2006; 29 (9): 769-84.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Russkiy Vrach Publishing House